Cabotegravir/Levonorgestrel Long-Acting MPT Injectable
Silica hydrogel-based long-acting injectable delivering CAB and levonorgestrel for 3-6 months duration. Currently in preclinical development.
Development Stage:
Preclinical – Advanced (Pre2)
Hormonal/Non-Hormonal:
Hormonal
Delivery Route & Method:
Systemic - Injectable (Subcutaneous)
Mechanism of Action:
Integrase strand-transfer inhibitor; progestin
Developer:
- CONRAD
Funding:
- Eastern Virginia Medical School
- National Institutes of Health (NIH)
- U.S. Agency for International Development (USAID)
Funding Mechanism:
NIH R33 (Project Horizon)
MATRIX
Past Funding:
National Institutes of Health (NIH R-61)
Active Ingredient(s):
- Cabotegravir
- Levonorgestrel
Product Indication(s):
- HIV
- Pregnancy